Effect of Remote Ischaemic Conditioning in Oncology Patients (ERIC-ONC)
Cardiotoxicity
About this trial
This is an interventional prevention trial for Cardiotoxicity focused on measuring remote ischaemic conditioning, remote ischemic conditioning, cardio-oncology, anthracycline, troponin, chemotherapy, myocardial reperfusion injury
Eligibility Criteria
Inclusion Criteria:
- Adult or teenage young adult cancer patients with capacity
- Anthracycline-regimen chemotherapy (de novo or re-challenge)
- Able to tolerate peripheral blood pressure arm cuff inflation
Exclusion Criteria:
- Recent myocardial infarction in previous 4 weeks
- previous diagnosis of dilated, hypertrophic cardiomyopathy, amyloid or Anderson-Fabry Disease
- peripheral vascular disease
- Chronic Kidney Disease (estimated glomerular filtration rate (GFR) < 30 ml/min)
- Taking sulphonylureas
- lymph node dissection patients will need BP cuff on contra-lateral arm
- Skip remote ischaemic conditioning (RIC) cycle if very low platelets (e.g. platelets < 50 x 10^9/L, can have RIC when platelet counts recover, as per protocol).
Sites / Locations
- University College London HospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Remote ischaemic conditioning
Control
Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes